

中醫藥學院通訊

SCM NEWSLETTER


2024年1月 | Jan 2024

連結全球：表彰卓越學者 賦能創新藥研

Global Connection: Honoring Scholars and
Shaping the Future of Medicine



學院LinkedIn
FOLLOW US

 School of Chinese
Medicine, HKBU



專題 Features

- 促進全球學術聯繫：第九屆榮譽教授頒授典禮暨研討會 03~05
Fostering global academic ties: Ninth Honorary Professorship Conferment Ceremony-cum-Seminar
- 跨界合作：第五屆國際創新藥物研發高峰論壇 06~10
Transdisciplinary collaboration: 5th International Summit on Innovative Drug Discovery

研究焦點 Research Focus

- 學院於研資局的研究撥款計劃獲取佳績 11
SCM's remarkable success in securing GRF and ECS grants advances Chinese medicine research
- 學院獲「主題研究計劃」撥款進行代謝性脂肪肝的代謝組學研究 12
SCM secures Theme-based Research Scheme funding to study metabolic associated fatty liver disease with metabolomics
- 研究卓越：學院十一位學者榮列全球前 2% 頂尖科學家 13
Research excellence: eleven SCM scholars listed among world's top 2% scientists
- 1% 頂尖榮譽：呂愛平教授榮膺 2023 年度最廣獲徵引研究學者 14
Top 1% honour: Professor Lyu Aiping named Highly Cited Researcher 2023
- 王凱亮博士獲頒 2023 年度國家優秀青年科學基金 14
Dr. Xavier Wong receives China's Excellent Young Scientists Fund 2023
- 首個香港研發治療便秘的中藥獲批在美展開臨床研究 15~16
The first locally-developed traditional Chinese medicine for constipation authorised to initiate clinical trials in the US
- 賈偉教授團隊揭示去氧膽酸在緩解非酒精性脂肪肝病中的角色 17~18
Professor Jia Wei's team unveils the role of deoxycholic acid in alleviating non-alcoholic fatty liver disease
- 李敏教授團隊開發創新的鈎藤化合物傳送方式治療阿茲海默症 19~20
Professor Li Min's team develops novel drug delivery system for Gouteng compound for Alzheimer's disease treatment
- 高加信博士團隊發現「異甘草素」具備治療胰臟癌潛力 21~22
Dr. Joshua Ko's team unveils treatment potential of isoliquiritigenin for pancreatic cancer

學術及專業活動

Academic and Professional Activities

學院動態 Highlights

學生・校友 Students・Alumni

學者新著 Staff Publications

聯絡資料 Contact Us


23~24

25~31

32~34

35

36



促進全球學術聯繫： 第九屆榮譽教授頒授典禮暨研討會

Fostering global academic ties: Ninth Honorary Professorship Conferment Ceremony-cum-Seminar



由香港浸會大學中醫藥學院主辦的第九屆榮譽教授頒授典禮暨研討會，於去年10月10日在校園順利舉行。典禮吸引了約500名本地和海內外學者、中醫師，以及學院師生到場或通過線上形式參與。

浸大校長衛炳江教授在典禮上致辭時，歡迎一眾來自德國、日本、中國、澳門和香港的榮譽教授，同時讚揚他們的卓越成就及對人類健康福祉的重大貢獻。醫學的未來取決於全球科學家和醫生的合作努力，浸大將通過與世界知名學府和專家的知識交流，推動醫療領域的創新和全球發展。

The School of Chinese Medicine (SCM) at Hong Kong Baptist University (HKBU) organised the Ninth Honorary Professorship Conferment Ceremony-cum-Seminar on campus on 10 October 2023. The ceremony attracted approximately 500 scholars from local, Mainland and overseas, Chinese medicine practitioners, and members of the SCM community, both physically and virtually.

Speaking at the Ceremony, Professor Alexander Wai, President and Vice-Chancellor of HKBU, welcomed the honorary professors from Germany, Japan, Mainland China, Macau and Hong Kong, and praised them for their outstanding achievements and contributions to human well-being. As the future of medicine hinges on global collaboration and concerted efforts from scientists and practitioners alike, HKBU will drive innovation and global development in the medical field through knowledge exchange with esteemed institutions and experts worldwide.



文樹德教授向學院贈送一頁翻譯成德文的中草藥典籍。

Professor Paul U. Unschuld presented SCM with a page of valuable German-translated Chinese herbal medicine ancient book.

研討會期間，榮譽教授們發表了發人深省的演講，主題涵蓋中醫藥文化和理論、中西醫協作、創新藥物研發、醫學研究以及未來醫療發展等。

學院期望能夠與榮譽教授們攜手進行跨學科研究合作，提升中醫藥學的診斷和治療效果，並透過中醫藥學與前沿技術的結合，加速研究成果轉化，從而改善人類健康。

During the seminar, the honorary professors delivered thought-provoking lectures on topics including the culture and theories of traditional Chinese medicine, integrative Chinese and Western medicine, innovative drug discovery, medical research and future healthcare advancement.

SCM hopes to collaborate with the honorary professors in transdisciplinary research projects to enhance the efficacy of diagnosis and treatment of Chinese medicine, as well as to accelerate the translation of research outcomes by integrating Chinese medicine with cutting-edge technologies, ultimately improving human health.



第九屆中醫藥學院榮譽教授 Ninth Cohort of SCM Honorary Professors (任期至2025年 Appointment until 2025)



- **後藤信哉教授 Professor Shinya Goto**
日本東海大學醫學部內科學系（心臟科）教授
Professor, Department of Medicine (Cardiology),
Tokai University School of Medicine, Japan



- **柯華珠教授 Professor Ke Hua Zhu, David**
安濟盛生物醫藥技術有限公司董事長及首席執行官
Chairman of the Board and Chief Executive Officer,
Angitia Biopharmaceuticals Limited



- **沈漢明教授 Professor Shen Hanming**
澳門大學健康科學學院副院長（教學）及講座教授
Associate Dean (Teaching) and Chair Professor,
Faculty of Health Sciences, University of Macau



- **唐旭東教授 Professor Tang Xudong**
中國中醫科學院首席研究員、學部委員、原副院長
Chief Professor, Fellow, Former Vice President,
China Academy of Chinese Medical Sciences



- **文樹德教授 Professor Paul U. Unschuld**
德國柏林夏麗特醫學院中國生命科學研究所所長
Director, Institute of Chinese Life Sciences, Charité Universitätsmedizin Berlin



- **王慶國教授 Professor Wang Qingguo**
國醫大師、北京中醫藥大學終身教授
National TCM Master; Tenured Professor, Beijing University of Chinese Medicine



- **胡定旭先生 Mr. Wu Ting Yuk, Anthony**
香港醫院管理局前主席
Former Chairman, Hospital Authority, Hong Kong



- **肖偉院士 Professor Xiao Wei**
中國工程院院士、江蘇康緣藥業股份有限公司現代中藥研究院院長
Academician, Chinese Academy of Engineering;
President, Modern Chinese Medicine Research Institute,
Jiangsu Kanion Pharmaceutical Co. Ltd.



- **徐宏喜教授 Professor Xu Hongxi**
上海中醫藥大學首席教授
Distinguished Professor, Shanghai University of Traditional Chinese Medicine



- **張忠德教授 Professor Zhang Zhongde**
廣東省中醫院院長
President, Guangdong Provincial Hospital of Chinese Medicine

榮譽教授名單按英文姓氏排列 Honorary Professors listed by alphabetical order of surname



跨界合作： 第五屆國際創新藥物研發高峰論壇

Transdisciplinary collaboration: 5th International Summit on Innovative Drug Discovery



學院舉辦的「第五屆國際創新藥物研發高峰論壇」於去年10月28日在校園圓滿舉行。活動提供平台予一眾來自藥物研發領域的領袖和學者就創新藥物研發的政策、研發的路徑和實戰經驗分享真知灼見。

高峰論壇的主題涵蓋「新視角解讀新藥研發的政策與生態」、「新時代新藥研發策略與轉化實踐」及「新藥發現者的創新發現之路」，邀得國家藥品監督管理局的官員，以及來自香港、澳門、中國內地和澳洲的醫藥產業企業家和知名學者發表共15場演說。是次論壇吸引了近500名人士於線上和線下參與，對於近



SCM organised The 5th International Summit on Innovative Drug Discovery on campus on 28 October 2023. The event brought together great minds in the drug discovery field to share insights on policies concerning research and development of innovative drugs as well as paths and practical experience of innovative drug discovery.

Carrying the themes of “New Horizons in Deciphering the Ecological Construction and Investment for New Drug Discovery and Development”, “Strategy and Translational Practice of New Drug Discovery and Development in the New Era” and “Innovator Insights into New Drug Discovery and Development”, the Summit featured 15 talks by officials from the National Medical Products Administration, pharmaceutical entrepreneurs and esteemed scholars from Hong Kong, Macau, Mainland China and Australia. This Summit, attracted approximately 500 attendees (in-person and online), took on particular

期政府關注中醫藥發展、基礎設施提升以及加強中西醫協作服務的舉措都具有特別的意義。適逢政府增加撥款支持「官產學研」的合作，讓科研成果商品化，更突顯論壇的時機恰到好處。



浸大校長衛炳江教授致歡迎辭時，肯定中醫藥的巨大價值，強調它在為公共衛生做出重大貢獻的潛力。他又分享了大學最近在科學和臨床研究取得的進展，表示浸大致力透過科學及標準化的方法促進健康與藥物研發。

署理院長賈偉教授展示了學院將研發成果轉化為創新方案的豐碩成果，並展望學院與企業加強合作，共同為人類健康福祉做出貢獻。

significance in light of the recent Government's focus on Chinese medicine development, infrastructure enhancement, and the strengthening of integrated Chinese-Western medicine services. The timing was also apt, coinciding with the Government's increased funding support for collaborations among governmental entities, industry, academia, and research sectors to commercialise research-and-development outcomes.

In his welcoming address, Professor Alexander Wai, President and Vice-Chancellor of HKBU, emphasised the immense value of Chinese medicine, highlighting its potential to make substantial contributions to public health. He also shared the University's latest achievements in scientific research and clinical studies, underscoring HKBU's dedication to the advancement of health and drug discovery through a scientific and standardised approach.

Professor Jia Wei, Acting Dean of Chinese Medicine, showcased the School's success stories and remarkable achievements in translating research results into innovative solutions. Looking ahead, SCM will foster collaborations with enterprises and universities to contribute to human well-being.



是次活動的志願者，主要由藥物發現（中藥現代化）理學碩士學位課程的學生組成。

The volunteers for this event were primarily composed of students from the Master of Science in Drug Discovery (Modernization of Chinese Medicine) programme.

第一節：新視角解讀新藥研發的政策與生態

主持：

- 賈偉教授 香港浸會大學中醫藥學院署理院長
- 支喆先生 華潤創業有限公司副總裁

講者：

- 徐曉強博士 國家藥品監督管理局藥品註冊管理司（中藥民族藥監督管理司）化學藥品處處長
- 于江泳博士 國家藥品監督管理局藥品註冊管理司（中藥民族藥監督管理司）中藥民族藥處處長
- 程龍教授 中國衛生信息和健康醫療大數據學會應用評估和保障專業委員會副秘書長
- 劉逸倫先生 博裕資本執行董事

第二節：新時代新藥研發策略與轉化實踐

主持：

- 卞兆祥教授 香港浸會大學協理副校長（中醫藥發展）、中醫藥學院臨床部主任
- 馮奕斌教授 香港大學中醫藥學院院長
- 張戈教授 香港浸會大學中醫藥學院副院長（研究）
- 林志秀教授 香港中文大學中醫學院院長

講者：

- 王勁松博士 和铂醫藥董事長及首席執行官
- 王曉良教授 天津藥物研究院藥物成藥性評價與系統轉化實驗室主任
- 柯華珠教授 安濟盛生物醫藥技術（廣州）有限公司董事長及首席執行官
- 梁子才博士 蘇州瑞博生物技術股份有限公司董事長及首席執行官
- 李明博士 滬港中科國際生物科技股份有限公司首席執行官
- 戴曉暢博士 聖諾醫藥執行董事、首席戰略官
- 朱貴東博士 科霸生物首席執行官

第三節：新藥發現者的創新發現之路

主持：

- 呂海濤博士 香港浸會大學中醫藥學院副教授
- 黃悅博士 上海生物醫藥前沿產業創新中心總監

講者：

- 朱依諄教授 澳門科技大學協理副校長、講座教授，歐洲科學院院士，依諾科技（香港）有限公司創始人
- 龔兆龍博士 思路迪醫藥董事長及首席執行官
- 鄭銘豪教授 西澳大學醫學院教授
- 何伊欣博士 安沛治療有限公司董事長及首席執行官

Session 1: New Horizons in Deciphering the Ecological Construction and Investment for New Drug Discovery and Development

Moderators:

- Professor Jia Wei | Acting Dean of Chinese Medicine, Hong Kong Baptist University
- Mr. Zhi Zhe | Vice President, China Resources Enterprise, Limited

Speakers:

- Dr. Xu Xiaoqiang | Director, Division of Chemical Drugs, Department of Drug Registration (Department of TCMs and Ethno-Medicines Regulation), National Medical Products Administration
- Dr. Yu Jiangyong | Director, Division of Traditional Chinese Medicines and Ethno-Medicines, Department of Drug Registration (Department of TCMs and Ethno-Medicines Regulation), National Medical Products Administration
- Professor Cheng Long | Deputy Secretary-General, Application Assessment and Assurance Committee of the Chinese Medical Information and Big Data Association
- Mr. Liu Yilun | Executive Director, Boyu Capital

Session 2: Strategy and Translational Practice of New Drug Discovery and Development in the New Era

Moderators:

- Professor Bian Zhaoxiang | Associate Vice-President (Chinese Medicine Development), Director of Clinical Division of School of Chinese Medicine, Hong Kong Baptist University
- Professor Feng Yibin | Director, School of Chinese Medicine, The University of Hong Kong
- Professor Zhang Ge | Associate Dean (Research), School of Chinese Medicine, Hong Kong Baptist University
- Professor Lin Zhixiu | Director, School of Chinese Medicine, The Chinese University of Hong Kong

Speakers:

- Dr. Wang Jingsong | Chairman and Chief Executive Officer, Harbour BioMed
- Professor Wang Xiaoliang | Director, Key Laboratory of Druggability Evaluation and System Translational Medicine, Tianjin Institute of Pharmaceutical Research
- Professor Ke Hua Zhu, David | Chairman and Chief Executive Officer, Angitia Biopharmaceuticals Limited
- Dr. Liang Zicai | Chairman and Chief Executive Officer, Suzhou Ribo Life Science Company Limited
- Dr. Li Ming | Chief Executive Officer, ZSHK Laboratories Limited
- Dr. Dai Xiaochang | Executive Director, Chief Strategy Officer of Sirnaomics Ltd.
- Dr. Zhu Guidong | Chief Executive Officer, Sparx Biopharmaceutical Corporation

Session 3: Innovator Insights into New Drug Discovery and Development

Moderators:

- Dr. Lyu Haitao | Associate Professor, School of Chinese Medicine, Hong Kong Baptist University
- Dr. Huang Yue | Director, Shanghai Biopharma Evolution

Speakers:

- Professor Zhu Yizhun | Associate Vice President, Chair Professor, Macau University of Science and Technology; Member of European Academy of Sciences & Arts; Founder of InnoDrug Lab. (HK) Co., Ltd.
- Dr. Gong Zhaolong, John | Chairman and Chief Executive Officer, 3D Medicines, Inc.
- Professor Zheng Minghao | Medical School, The University of Western Australia
- Dr. He Yixin | Chairman and Chief Executive Officer, Aptacure Therapeutics Limited

疫情過後，學院積極恢復各類型的學術交流活動。我們邀請了海內外專家前來分享他們的見解，為我們充滿活力的教學科研社群注入新的視角。

In the wake of the pandemic, the School has been revitalising its academic exchange activities. Distinguished experts from abroad have been invited to share their insights, infusing fresh perspectives into our vibrant educational and research communities.

北京中醫藥大學徐安龍校長來訪 Visit by BUCM President Xu Anlong



學院很榮幸地邀請到北京中醫藥大學校長徐安龍教授於去年7月蒞臨進行交流訪問。期間，徐教授以「從免疫調控多元性到中醫藥抗病毒機理」為題發表演說，重點介紹課題組在抗體重排、天然免疫識別及免疫基因表達

多元性調控等領域的創新研究工作，分享從中西醫結合視角革新解讀中醫藥治療原理的最新進展，以及對人工智慧 (AI) 如何賦能中藥現代化發展進行了簡要展望。

SCM was honoured to have invited Professor Xu Anlong, President of Beijing University of Chinese Medicine (BUCM), to visit the School last July. Professor Xu delivered a distinguished lecture entitled "From the Diversity of Immune Regulation to the Anti-viral Mechanisms of Traditional Chinese Medicine (TCM)," sharing the latest progress made by his research team, as well as his insights on antibody rearrangement, natural immune recognition, immune gene expression regulation in the context of infectious diseases, as well as translational application of the immune-regulatory strategies to the therapeutic discovery of TCM and associated formulae against the complex diseases. Professor Xu concluded the lecture with an open discussion on the potential applicability and the scientific value of artificial intelligence techniques in future explorations of TCM.

哈佛學人：從過去的療法到未來的治療

Harvard scholar: from past remedies to future cures

在「浸大傑出學人講座系列」中，哈佛醫學院知名教授 Timothy John Mitchison 以「塑造歷史的藥物與未來藥物發現的前景」為題作演講，追溯了藥理學的軌跡，從嗎啡的「鑰匙與鎖」概念到盤尼西林（青黴素）的「魔法子彈」原理，再到基因治療的新興領域。講座於去年11月6日舉行，吸引了約100名參加者，引發了他們對藥物發現的豐富歷史和精彩未來的深思探索。

Under the banner of the "HKBU Distinguished Lecture Series," Professor Timothy John Mitchison from Harvard Medical School illuminated a crowd of about 100 participants with a riveting talk titled "Medicines that shaped history and prospects for future drug discovery". The lecture, held on 6 November 2023, traced the fascinating trajectory of pharmacology, from the "key and lock" concept of Morphine to the "magic bullet" principle of Penicillin, and onto the emerging frontiers of gene therapy. The seminar provided a thought-provoking exploration of the rich history and exciting future of drug discovery.



鮑儒德教授擔任學院客座教授

Professor Rudolf Bauer joins SCM as Visiting Professor

由浸大黃英豪博士傑出客座教授計劃支持，奧地利格拉茨大學藥物科學研究所生藥學系主任鮑儒德教授於去年7月至8月期間加入學院擔任客座教授。訪問期間，鮑教授為教職員和研究生主講了三場講座，分享了他在格拉茨大學生藥學研究領域的豐富經驗，並就腸道菌群對草藥活性的作用及化學計量學在藥用植物藥物發現中的應用等題目提供了寶貴的見解。鮑教授更寄語中醫藥研究人員要確保將中醫藥這門獨特的傳統代代相傳，並朝著國際科學基準和現代化的方向邁進。




With the support from HKBU Dr. Kennedy Wong Distinguished Visiting Professorship Scheme, Professor Rudolf Bauer, Head of the Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, joined SCM as Visiting Professor from July to August 2023. Professor Bauer presented three thought-provoking lectures sharing his vast experience in pharmacognosy research at the University of Graz, as well as his valuable insights on the role of gut microbiota for the activity of herbal medicine and the application of chemometric concepts for drug discovery in medicinal plants. Professor Bauer encourages our researchers to ensure traditional Chinese medicine is passed down from generation to generation, ultimately advancing towards international scientific benchmarks and modernisation.

葉克強教授分享對早期診斷阿茲海默症的見解

Professor Ye Keqiang shares insights on early Alzheimer's detection

學院於去年8月14日舉辦講座，由深圳先進技術研究院葉克強教授主講，題為「阿茲海默症的發病機制及早期診斷」。講座圍繞 C/EBP β /AEP 神經信號通路在阿茲海默症和帕金森症的發病和病情進展中的關鍵作用。葉教授的研究突顯了 AEP 酶是早期診斷神經退行性疾病的潛在關鍵因素，加深研究人員對阿茲海默症和帕金森症的病理特徵的理解。

SCM held a seminar entitled "Pathogenesis and Early Diagnosis of Alzheimer's Disease" by Professor Ye Keqiang from the Shenzhen Institute of Advanced Technology on 14 August 2023. The seminar centered on the pivotal role of C/EBP β /AEP signaling in the onset and progression of both Alzheimer's disease (AD) and Parkinson's disease (PD). Professor Ye's findings underscore the potential of AEP enzyme as a key factor in the early diagnosis of neurodegenerative diseases, comprehending our understanding of the pathological features seen in AD and PD.



學院於研資局的研究撥款計劃獲取佳績

SCM's remarkable success in securing GRF and ECS grants advances Chinese medicine research

學院在研究資助局（研資局）最新一輪的競逐研究資助計劃中取得卓越成績，獲得了五項優配研究金（GRF）和三項傑出青年學者計劃（ECS）撥款，在激烈的競爭中脫穎而出，保持在同儕中的領導地位。學院在優配研究金撥款中獲得了超過700萬港元的資助，金額較上年度增加了27%。另外，學院又獲得約400萬港元的傑出青年學者計劃撥款，充分體現對新晉學者的支持和認可。

本年度獲資助項目涵蓋一系列中醫藥和整合醫學領域的創新研究，當中不乏跨學科研究方法。研究成果有助拓闊治療選擇，揭示中草藥和療法的機制，提供促進健康和疾病管理的整合方法。

學院一直走在中醫藥研究的前沿，致力通過創新研究和跨學科研究來推進科學發展。這些資助項目展示了學院強大的研究能力，以及憑藉各項具影響力的科研成果，為社會作出貢獻的精神和決心。

SCM has achieved another year of strong performance in competitive research grants. In the latest round of the Research Grants Council (RGC)'s funding schemes, the School won five General Research Fund (GRF) and three Early Career Scheme (ECS) grants, maintaining its leadership among peer institutions. In addition to securing over \$7 million in GRF grants, which represents a 27% increase over last year's funding amount, the School was also awarded ECS grants totaling \$4 million, demonstrating its support for young scholars.

The awarded projects showcase an array of innovative research in Chinese medicine and integrated medicine using interdisciplinary methodologies. The outcomes can potentially advance treatment options, uncover mechanisms of Chinese herbs and therapies, and promote integrative approaches to health and disease management.

SCM has been at the forefront of Chinese medicine research, and these grants further demonstrate its commitment to advancing the field through innovative research and interdisciplinary approaches. The achievement also reflects its strong research capabilities and its dedication to contributing to the society through impactful research outcomes.

優配研究金 General Research Fund (GRF)

Principal Investigator	Project Title
Professor Bian Zhaoxiang	Investigation of abdominal pain management in diarrhea-predominant irritable bowel syndrome via short-chain fatty acids/GLP-1 axis
Dr. Cheung Chat-pan, Kenneth	Investigating and examining the role of Hyocholic acid signalling in athero-immunometabolism
Dr. Cheung King-ho	Elucidating the role of TRPM7 channel and its therapeutic potential in neuroinflammation of Alzheimer's disease
Professor Han Quanbin, Simon	Radix Astragali polysaccharide RAP: an ideal intestinal M cell-targeted oral vaccine carrier and immunostimulant?
Professor Zhang Ge	Macrophagic sclerostin loop2-ApoER2 interaction participates in the suppressive effect of sclerostin on atherosclerosis

傑出青年學者計劃 Early Career Scheme (ECS)

Principal Investigator	Project Title
Dr. Liu Jin	Blocking exosome release from atrophic skeletal muscle to strengthen bone: a novel therapeutic strategy for muscle atrophy-associated bone loss?
Dr. Tan Hor Yue	Role of lysyl oxidase-like-4 in modulating the macrophage transition in ulcerative colitis
Dr. Wong Hoi-leong, Xavier	Investigating the regulatory role of phenethylamine for serotonin reuptake in the pathogenesis of diarrhea-predominant Irritable Bowel Syndrome

（資助結果只提供英文版）


學院獲「主題研究計劃」撥款進行代謝性脂肪肝的代謝組學研究

SCM secures Theme-based Research Scheme funding to study metabolic associated fatty liver disease with metabolomics

由學院署理院長及張安德中醫藥教授賈偉教授，以及教學科研部研究助理教授張質彬博士領導的一項名為「腸道菌群—宿主共代謝失衡在代謝相關脂肪性肝病中的研究」，獲研資局第13輪「主題研究計劃」撥款超過港幣720萬元。這項為期一年的探索性研究撥款，將支持研究團隊取得初步研究成果，為腸道菌群代謝研究奠定基礎。

代謝性脂肪肝與二型糖尿病共存且互為影響，增加了出現嚴重臨床症狀的風險，為世界各地帶來沉重的公共衛生負擔。腸道菌群與其宿主在代謝過程方面的相互作用，在近年受到廣泛關注，並成為一個前沿研究領域。是項研究旨在探索代謝性脂肪肝與二型糖尿病之間的分子聯繫，並特別關注宿主與腸道菌群的相互作用。

賈偉教授表示：「這項研究將鑑別出在二型糖尿病患者和非患者身上，與代謝性脂肪肝發展有密切關係，並存在於血液中的關鍵菌群代謝物，以及腸道菌群的特徵。團隊並會建立一個數據庫，用作鑑別不同類別的菌群，以及能用於與二型糖尿病相關的代謝性脂肪肝的早期檢測和風險評估的代謝物。是項研究的目的，是藉著探索這些相互作用，確立香港在代謝性脂肪肝與二型糖尿病轉化研究的領導地位。」



A research project titled “Dysregulated Host – Gut Microbiota Co-Metabolism in Metabolic Associated Fatty Liver Disease”, led by Professor Jia Wei, Acting Dean of Chinese Medicine and Cheung On Tak Endowed Professor in Chinese Medicine, and Dr. Kenneth Cheung, Research Assistant Professor of the Teaching and Research Division (CMTR), has been awarded over HK\$7.2 million in research funding from the Theme-based Research Scheme (13th round) under RGC. This one-year exploratory funding will enable the research team to produce preliminary results which lay the foundation for the research of the gut microbiota metabolism, a far-reaching and promising research area, with huge potential benefits to human health.

Metabolic associated fatty liver disease (MAFLD) coexists and acts synergistically with type 2 diabetes mellitus (T2DM) to increase the risk of adverse clinical outcomes, resulting in substantial public health burdens worldwide. While the interactions between the host and gut microbiota in terms of metabolism have in recent years gained significant attention as a cutting-edge research area, the objective of this study is to shed light on the molecular connections between MAFLD and T2DM, with a specific focus on host-gut microbiota interactions.

Professor Jia said: “The research will identify key microbial metabolites in the blood and gut microbiota signatures that are closely associated with the development of MAFLD in individuals, both with and without comorbid T2DM. The team will also create a database to identify microbial species and metabolites that can be used for early detection and risk assessment of MAFLD associated with T2DM. By exploring these interactions, this research aims to establish Hong Kong as a leader in translational research on MAFLD and T2DM.”

研究卓越：學院十一位學者榮列全球前 2% 頂尖科學家

Research excellence: eleven SCM scholars listed among world's top 2% scientists

學院十一位學者成功躋身美國史丹福大學 2023 年全球前 2% 頂尖科學家排行榜，成就非凡。本年度學院的頂尖科學家人數再創新高，反映一眾研究人員追求卓越的堅毅和決心，同時彰顯學院的研究實力及其在學術界的影響力。

恭喜學院學者躋身全球前 2% 頂尖科學家排行榜（按英文姓氏排列）：

Eleven SCM scholars have achieved the remarkable feat of being listed among the world's top 2% most-cited scientists in 2023, announced by Stanford University in the US. The number of most-cited scientists from SCM reached a record high this year, underscoring the dedication of our Chinese medicine researchers and highlighting the School's research strengths and its profound impact on the academic community.

Congratulations to the world's top 2% most-cited scientists from SCM (listed in alphabetical order by surname):

姓名及學術領域 Name & Subject Field



卞兆祥教授
臨床醫學
Professor Bian Zhaoxiang
Clinical Medicine



陳虎彪教授
化學
Professor Chen Hubiao
Chemistry



韓全斌教授
化學
Professor Han Quanbin, Simon
Chemistry



賈偉教授
臨床醫學
Professor Jia Wei
Clinical Medicine



李敏教授
臨床醫學與生物醫學研究
Professor Li Min
Clinical Medicine and Biomedical Research



呂愛平教授
臨床醫學
Professor Lyu Aiping
Clinical Medicine



陳可瑜博士
臨床醫學
Dr. Tan Hor Yue
Clinical Medicine



易濤博士
化學
Dr. Yi Tao
Chemistry



張戈教授
臨床醫學
Professor Zhang Ge
Clinical Medicine



張宏杰教授
化學
Professor Zhang Hongjie
Chemistry



趙中振教授
化學
Professor Zhao Zhongzhen
Chemistry

1% 頂尖榮譽：呂愛平教授 榮膺2023年度最廣獲徵引研究學者

Top 1% honour: Professor Lyu Aiping named Highly Cited Researcher 2023




浸大副校長（研究及拓展）兼黃英豪博士中醫藥教授呂愛平教授於國際知名研究文獻資料庫Web of Science™的「跨領域」類別所發表的論文被科睿唯安（Clarivate）評為引用次數最多的1%，獲譽為本年度全球最廣獲徵引研究學者之一，與來自全球67個國家和地區不同研究領域共6,849位頂尖專家齊名。呂教授更是浸大2023年度唯一獲此殊

榮的學者，他再獲殊榮力證了中醫藥學者的學術及科研地位備受國際矚目，中醫藥藥物研發在全球的影響力亦日漸提升。

Professor Lyu Aiping, Vice-President (Research and Development) of HKBU and Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine, has been recognised as "Highly Cited Researcher" for his publications ranked among Clarivate's top 1% most cited publications for the category "cross-field" in Web of Science™. Along with 6,849 researchers from 67 countries and regions across various research fields, Professor Lyu earned this extraordinary accolade in recognition of his academic publications. He is the sole researcher from HKBU to be honoured with this recognition in 2023. His accolade once again demonstrates the academic and research status of Chinese medicine scholars, arousing international attention. The global influence of Chinese medicine drug discovery is also growing steadily.

王凱亮博士獲頒2023年度 國家優秀青年科學基金

Dr. Xavier Wong receives China's Excellent Young Scientists Fund 2023




教 學科研部副教授王凱亮博士獲頒國家自然科學基金2023年度優秀青年科學基金項目（港澳）。王博士的研究項目「探索二型糖尿病的分子機制及治療策略」將獲200萬元人民幣的資助，支持相關研究工作。

Dr. Xavier Wong, Associate Professor of CMTR, has been awarded the Excellent Young Scientists Fund (Hong Kong and Macao) under the National Natural Science Foundation of China (NSFC). Dr. Wong's awarded project, "Investigating the Molecular Mechanism and Therapeutic Strategy for Type 2 Diabetes," will receive funding of RMB 2 million to support its research endeavours.

首個香港研發治療便秘的中藥獲批在美展開臨床研究

The first locally-developed traditional Chinese medicine for constipation authorised to initiate clinical trials in the US



浸大協理副校長（中醫藥發展）、中醫藥學院臨床部主任、中藥創新研發中心總裁卞兆祥教授及其「中藥創新研發中心」團隊，研發了治療慢性便秘的創新中藥。該藥已獲美國食品及藥物管理局批准展開第一期臨床研究。這是香港首個以中草藥為基礎、並獲准在美國展開臨床研究的新藥研發項目。

目前全球約14%的人口飽受慢性便秘困擾。考慮到為患者提供更佳藥物，中藥創新研發中心基於先前對傳統中草藥古方「麻子仁丸」的先導性臨床研究及基礎研究，與芝加哥大學及澳門大學等合作研製新藥 CDD-2101。CDD-2101 的主要成

Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) of HKBU, Director of the Clinical Division (CLNC) of SCM, and Director of The Centre for Chinese Herbal Medicine Drug Development (CDD), along with his team at CDD, have developed an innovative traditional Chinese medicine for treating chronic constipation. The medicine has been approved by the US Food and Drug Administration to commence phase one of clinical trials. This is the first locally-developed new medicine based on traditional Chinese herbs in Hong Kong that is approved for clinical trials in the US.

Currently, about 14% of the global population suffer from chronic constipation. With the aim of providing a better treatment for patients, CDD has collaborated with the University of Chicago and the University of Macau to develop the new drug CDD-2101, based on previous pilot clinical research and fundamental



份包括火麻仁、大黃、厚樸、苦杏仁、麩炒枳實、白芍共六種中草藥。

卞兆祥教授表示：「CDD-2101是以傳統中草藥配方結合先進科技研發的創新藥物，並按照國際標準研製。是次獲美國食品及藥物管理局批准進行臨床試驗，是香港中藥發展的重要里程碑。」

CDD-2101將於2024年內在美國完成第一期臨床研究。藥物研發計劃的最終目標，是收集足夠的安全性和療效數據，以獲得美國食品及藥物管理局審批 CDD-2101成為可銷售的新藥。


research on the traditional Chinese herbal formula "Mazi Ren Wan". The main ingredients of CDD-2101 include hemp seed, rhubarb, officinal magnolia bark, bitter apricot seed, bran stir-fried immature orange fruit, and white peony root.

Professor Bian said: "CDD-2101 is an innovative drug developed by combining traditional Chinese herbal formulas with advanced technology and is manufactured in accordance with international standards. The approval to conduct clinical trials by the US Food and Drug Administration is an important milestone in the development of Chinese medicine in Hong Kong."

CDD-2101 will complete its first phase of clinical trials in the US within 2024. The ultimate goal of the drug development plan is to collect enough safety and effectiveness data to gain approval from the US Food and Drug Administration for CDD-2101 to become a marketable new drug.

賈偉教授團隊揭示去氧膽酸在緩解非酒精性脂肪肝病中的角色

Professor Jia Wei's team unveils the role of deoxycholic acid in alleviating non-alcoholic fatty liver disease



由學院署理院長兼學院轄下的香港中醫藥表型組學研究中心主任賈偉教授領導的研究，揭示了一種在人體腸道產生的膽汁酸「豬去氧膽酸」（HDCA）能減少肝臟的脂肪積聚和發炎，顯示出對治療「非酒精性脂肪肝病」的巨大潛力。這項研究成果已收錄在國際知名科學期刊《Cell Metabolism》。

非酒精性脂肪肝的特點是肝臟中有過多脂肪積聚，而且並非由攝取酒精所引起。目前，全球非酒精性脂肪肝的患病率不斷增加，市面上尚未有獲准出售的治療藥物。

HDCA 是一種在人體內自然存在的化合物，它在膽酸生產和腸肝代謝軸中起著重要的作用。賈教授的團隊發現，同時患有非酒精性脂肪肝病和二型糖尿病的人，體內 HDCA 的水平較沒有這些病的人低。這項觀察促使團隊探索 HDCA 的潛在治療角色。

A research led by Professor Jia Wei, Acting Dean of Chinese Medicine and Director of the School's Hong Kong Traditional Chinese Medicine Phenome Research Centre, has discovered that hyodeoxycholic acid (HDCA), a bile acid generated in human intestine, can reduce fat accumulation and inflammation in the liver, demonstrating its strong therapeutic potential for non-alcoholic fatty liver disease (NAFLD). The outcomes of this research endeavor have been formally documented in the esteemed international scientific journal, *Cell Metabolism*.

NAFLD is characterised by the build-up of excessive fat in liver cells that is not caused by alcohol consumption. Currently, its global prevalence has been increasing over time, and there are no therapeutic drugs available for sale on the market.

HDCA is a compound found naturally in our bodies, which plays a significant role in bile acid production and in the gut-liver metabolic axis. Professor Jia's team found that

在一系列的對照實驗中，研究團隊探究 HDCA 在非酒精性脂肪肝病的小鼠模型中的治療效果。結果顯示 HDCA 不僅減少了肝臟中的脂肪積累和炎症，還提升了有益腸道菌群的數量。這些效果並非直接在肝細胞產生作用，而是通過調節腸肝代謝軸來發揮相關效果，反映腸道健康在肝病中的關鍵角色。

這項研究在理解非酒精性脂肪肝病的病理生理學方面邁出了一大步，為干預療法提供了一種潛在的新途徑，具有非常重要的臨床意義。賈教授目前正在中國內地組織一項對照臨床試驗，以評估 HDCA 對脂肪肝病患者的安全性和有效性。

賈教授的突破性研究強調了腸肝代謝軸在疾病管理中的關鍵角色。學院對每一項新發現都深感驕傲，因為這意味著我們更理解新的治療方法、改善病患病況，以至人類生物學。

individuals with NAFLD and type 2 diabetes have lower levels of HDCA compared to those without these conditions. This observation led the team to explore HDCA's potential therapeutic role.

In a series of controlled experiments, HDCA was administered to mouse models with NAFLD. The results were encouraging: HDCA not only reduced fat accumulation and inflammation in the liver but also improved the population of beneficial gut bacteria. Interestingly, these effects were not due to direct action on liver cells, but rather through modulation of the gut-liver metabolic axis, demonstrating the critical role of gut health in liver disease.

This research is a significant stride forward in understanding the pathophysiology of NAFLD and offers a potential new avenue for therapeutic intervention. Professor Jia is presently organising a controlled clinical trial in Mainland China to evaluate the safety and efficacy of HDCA for patients with fatty liver disease.

Professor Jia's groundbreaking study underscores the crucial role of the gut-liver metabolic axis in disease management. At SCM, we celebrate each discovery as a step closer to new treatments, improved patient outcomes, and a deeper understanding of human biology.

nature reviews endocrinology

Research highlights

NAFLD

Bile acid species shows potential for NAFLD

A pressing need exists for effective drugs to treat nonalcoholic fatty liver disease (NAFLD), which affects around a quarter of the population worldwide. A new study in *Cell Metabolism* now shows that a bile acid, hyodeoxycholic acid (HDCA), is depleted in patients with NAFLD and shows therapeutic potential in mouse models of NAFLD.

nature reviews gastroenterology & hepatology

Research highlights

NAFLD

HDCA ameliorates NAFLD in mice

A new study published in *Cell Metabolism* has suggested a potential therapeutic role for hyodeoxycholic acid (HDCA), a bile acid modified by the gut microbiota, in the treatment of nonalcoholic fatty liver disease (NAFLD).


First, the researchers observed in both clinical cohorts and mouse models that NAFLD severity inversely correlated with serum levels of HDCA. Then, they assessed whether treatment with HDCA influences NAFLD. In several high-fat-diet-induced mouse models

賈偉教授對非酒精性脂肪肝具影響力的研究，獲得《自然》旗下兩份學科評論期刊的關注，突顯了 HDCA 在肝臟健康和腸道微生物互動中的關鍵角色，標誌著治療上的突破。

Professor Jia Wei's influential NAFLD research, capturing the attention of *Nature Reviews* in two disciplines, underscores HDCA's promising role in liver health and gut microbiota interplay, marking a therapeutic breakthrough.

李敏教授團隊開發創新的 鈎藤化合物傳送方式治療阿茲海默症

Professor Li Min's team develops novel drug delivery system for Gouteng compound for Alzheimer's disease treatment



學院副院長（教與學）李敏教授及教學科研部研究助理教授 Ashok Iyaswamy 博士率領的研究團隊，開發了一種創新的藥物傳送方式，用作治療阿茲海默症。研究結果已刊登於國際學術期刊《Nature-Signal Transduction and Targeted Therapy》。

阿茲海默症是最常見的一種認知障礙症，患者的腦細胞會退化並死亡，其特徵是大腦積聚澱粉樣蛋白和磷酸 tau 蛋白，導致大腦認知功能下降。香港有10多萬長者患有認知障礙症，預計到了2039年將飆升至超過33萬人。

A research team led by Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine, and Dr. Ashok Iyaswamy, Research Assistant Professor of CMTR, has developed a novel drug delivery system for Alzheimer's disease (AD). The research findings have been published in the international academic journal *Nature-Signal Transduction and Targeted Therapy*.

AD is the most common type of dementia in which the brain cells degenerate and die, characterised by a build-up of amyloid-beta and phospho-tau protein in the brain, resulting in the decline of the brain's cognitive functions. In Hong Kong, more than 100,000 elderly suffer from dementia and the number is anticipated to soar to more than 330,000 by 2039. There is no curative treatment for AD at present. HKBU's



ARTICLE OPEN

Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer's disease

Ashok Iyaswamy^{1,✉}, Abhimanyu Thakur^{2,3,✉}, Xin-Jie Guan¹, Senthilkumar Krishnamoorthi¹, Tsz Yan Fung¹, Kejia Lu¹, Isha Gaurav⁴, Zhijun Yang⁴, Cheng-Fu Su¹, Kwok-Fai Lau⁵, Kui Zhang^{2,3}, Roy Chun-Laam Ng⁶, Qizhou Lian^{7,8,9}, King-Ho Cheung¹, Keqiang Ye¹⁰, Huanhuan Joyce Chen^{2,3,✉} and Min Li^{1,✉}

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the predominant impairment of neurons in the hippocampus and the formation of amyloid plaques, hyperphosphorylated tau protein, and neurofibrillary tangles in the brain. The overexpression of amyloid- β precursor protein (APP) in an AD brain results in the binding of APP intracellular domain (AICD) to Fe65 protein via the C-terminal Fe65-PTB2 interaction, which then triggers the secretion of amyloid- β and the consequent pathogenesis

目前阿茲海默症並無根治的方法。浸大過往研究發現，鈎藤的生物活性化合物柯諾辛鹼 -B，能有效治療阿茲海默症。然而，保護大腦免受血液中潛在有害物質影響的血腦屏障，會影響大腦吸收柯諾辛鹼 -B。

為解決這個問題，李敏教授與 Ashok Iyaswamy 博士聯同本地、內地和海外科學家組成研究團隊，開發了一種利用外泌體將柯諾辛鹼 -B 傳遞至大腦的新方法。

外泌體是由細胞釋放出來的細胞外囊泡，可以成為輸送藥物的載體。柯諾辛鹼 -B 具有促進自噬活動的特性，而自噬機制在維持神經元健康中發揮極為重要的作用。研究團隊將柯諾辛鹼 -B 載入經改造的外泌體中，再注射至患有阿茲海默症的小鼠體內，以評估其作為阿茲海默症藥物的潛力。結果顯示，載有柯諾辛鹼 -B 的改造外泌體，可提升小鼠的自噬活動，並穿過血腦屏障，將柯諾辛鹼 -B 傳遞至大腦，從而令累積的澱粉樣蛋白減少三成。研究人員又針對阿茲海默症小鼠進行各種行為測試，結果發現注射載有柯諾辛鹼 -B 的改造外泌體，可恢復 25% 認知和活動能力。

李敏教授表示：「外泌體很有潛力成為一種向大腦輸送藥物，用以治療阿茲海默症的新方法。雖然還需要進行更多探索，但這項研究為未來發展出治療阿茲海默症的藥物帶來希望，期望最終可以造福長者、神經退化的高風險人士，以及神經退化性疾病的患者。」

previous research projects found that Corynoxine-B, a bioactive compound of Gouteng, is effective in treating AD. However, the blood-brain barrier which protects the brain from potentially harmful substances in the bloodstream affects its uptake in brain.

To tackle this problem, a research team comprising Professor Li Min and Dr. Ashok Iyaswamy, along with other local, Mainland and overseas scientists, have developed a novel approach to deliver Corynoxine-B to the brain using exosomes.

Exosomes are extracellular vesicles released by cells which can be utilised as vehicles for drug delivery. Corynoxine-B is a natural inducer of autophagy which plays a crucial role in maintaining neuronal health. The research team loaded it into the engineered exosomes and injected it to the mice with AD to evaluate its potential as a therapeutic agent for the disease. Results show that engineered exosomes loaded with Corynoxine-B could enhance autophagy in mice, and were able to cross the blood-brain barrier to deliver Corynoxine-B to the brain, resulting in a 30% reduction of accumulated amyloid-beta protein. In addition, various behavioural tests conducted on mice with AD showed that the application of engineered exosomes loaded with Corynoxine-B resulted in 25% recovery of the cognitive and locomotor behaviour.

Professor Li said: "Our study suggests that exosomes could be a promising novel approach for drug delivery to the brain and AD's treatment. While further research is necessary, this study instills hope that a potential cure for AD may be achievable in the future, ultimately benefiting the elderly, individuals at high risk of neurodegeneration, and patients with neurodegenerative diseases."

高加信博士團隊發現「異甘草素」 具備治療胰臟癌潛力

Dr. Joshua Ko's team unveils treatment potential of isoliquiritigenin for pancreatic cancer



教學科研部副教授高加信博士領導的研究發現，從中草藥「甘草」提取的一種類黃酮物質「異甘草素」，可抑制胰臟癌發展，並可提高傳統胰臟癌化療藥的功效。這是首次有研究團隊闡述異甘草素對抗胰臟癌的潛力。研究結果已發表於國際學術期刊《Phytomedicine》，並在於意大利都靈舉行的 2023 年歐洲癌症研究協會年會上報告。

胰臟癌是香港第四大致命癌症。根據國際癌症研究機構發表的《2020 全球癌症統計數據》，胰臟癌患者的死亡比率高於 93%。胰臟癌的治療方案以手術及化療藥為主，當中只有約兩成患者適合

A research led by Dr. Ko Ka-shun, Joshua, Associate Professor of CMTR, found that isoliquiritigenin (ISL), a flavonoid isolated from the Chinese herbal medicine licorice, can inhibit pancreatic cancer progression and may enhance the efficacy of conventional chemotherapeutic drugs in treating pancreatic cancer. It is the first time that a research group reported the anticancer potential of ISL in treating pancreatic cancer. The research findings have been published in the international academic journal *Phytomedicine* and presented in the Annual Congress of the European Association for Cancer Research 2023 in Torino, Italy.

Pancreatic cancer is the fourth leading cause of cancer deaths in Hong Kong. According to the Global Cancer Statistics 2020 released by the International Agency for Research on Cancer, the mortality-to-incidence ratio of pancreatic cancer is greater than 93%. The treatment of pancreatic cancer primarily consists

Phytomedicine 106 (2022) 154406



Contents lists available at ScienceDirect

Phytomedicine

journal homepage: www.elsevier.com/locate/phymed



Original Article

Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy

Zhu Zhang^{a,b,c,1}, Wen-qing Chen^{a,b,1}, Shi-qing Zhang^{d,1}, Jing-xuan Bai^a, Bin Liu^e, Ken Kin-Lam Yung^{b,c,*}, Joshua Ka-Shun Ko^{a,f,*}

^a Teaching and Research Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China

^b Department of Biology, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China

^c Golden Meditech Centre for NeuroRegeneration Sciences, Hong Kong Baptist University, Hong Kong SAR, China



進行切除手術，且術後的復發率很高，至於無法接受切除手術或已擴散的個案，則可服用化療藥「吉西他濱」，但以此藥為基礎的組合治療會出現強烈的抗藥性，其毒性亦會造成系統性的影響。

為尋找其他治療胰臟癌的方案，研究團隊透過網絡藥理學，就所有胰臟癌的潛在疾病標記物，以及藥用植物甘草中的植物化學物所具備的生物治療活性進行篩選，發現異甘草素有潛力成為治療胰臟癌的藥物，然後通過一系列的細胞實驗，證明異甘草素能抑制胰臟癌細胞的生長，並促進癌細胞的程序性凋亡。研究團隊進一步利用小鼠腫瘤模型，研究異甘草素在體內抑制胰臟癌細胞生長的功效，結果顯示異甘草素的治療效果與吉西他濱相若，並發現異甘草素對小鼠的副作用比吉西他濱少。

目前胰臟癌的一線化療藥物，如吉西他濱和5-氟尿嘧啶 (5-FU)，均會促進自噬，有利癌細胞生長，產生抗藥性情況，因而影響治療效果。為探索異甘草素紓緩吉西他濱和5-FU 抗藥性的潛力，研究團隊進行實驗，把兩種化療藥結合異甘草素同時使用，結果顯示異甘草素能阻斷自噬，促進癌細胞的凋亡，提升化療藥的治療效果。

高加信博士表示：「研究結果開闢了新方向，探討把異甘草素開發成嶄新的自噬抑制劑，用作治療胰臟癌。我們希望與其他研究夥伴合作，進一步評估異甘草素在治療胰臟癌的有效性，及其潛在的臨床應用。」

of surgery and chemotherapeutic drugs. However, only 20% of patients are suitable for resection and the recurrence rate is high. In non-resectable cases and metastatic pancreatic cancer patients, the chemotherapeutic drug gemcitabine (GEM) remains the mainstream treatment. Nevertheless, GEM-based combination therapy exhibits profound chemoresistance with serious systemic toxicity.

In the search for alternative treatments for pancreatic cancer, the research team screened all the potential pancreatic cancer disease markers and the biological therapeutic activities of phytochemicals from the medicinal plant *Glycyrrhiza glabra* (licorice, or Gancan in Chinese) using network pharmacology, identifying ISL as a potential anticancer agent for the treatment of pancreatic cancer. With a series of cell experiments, the team demonstrated that ISL suppressed the growth and induced apoptosis (programmed cell death) of pancreatic cancer cells. The research team further employed a mice tumor model to investigate the efficacy of ISL in inhibiting pancreatic cancer cell growth *in vivo*. The results showed that ISL demonstrated treatment effects comparable to that of GEM and showed fewer side effects in mice compared with GEM.

Current first-line chemotherapeutic drugs for pancreatic cancer, such as GEM and 5-fluorouracil (5-FU), induce autophagy which favours the growth of cancer cells and causes chemoresistance, and thus jeopardises their treatment effects. To explore ISL's potential in counteracting the chemoresistance of GEM and 5-FU, the research team set up experiments with pancreatic cancer cells treated with GEM or 5-FU together with ISL. The results showed that ISL can enhance the treatment effects of chemotherapeutic drugs by blocking autophagy, which is conducive to the death of cancer cells.

“The findings in this study open a new avenue for developing ISL as a novel autophagy inhibitor in the treatment of pancreatic cancer. We hope to collaborate with other research partners to further evaluate the effectiveness and potential clinical application of ISL in treating pancreatic cancer,” said Dr Ko.

學院舉辦2023香港名貴中藥質量控制高峰論壇 SCM hosts the 2023 HK Summit of Quality Control of Valuable Chinese Medicines



由學院及香港名貴中藥檢定中心共同舉辦的「2023香港名貴中藥質量控制高峰論壇」，於去年10月29日在校園舉行。今年論壇的主題是「政府部門在中藥質量控制方面的系統工作」，吸引來自政府部門、業界和學界近 200 名人士參加。

是次論壇邀得來自政府部門、業界和學界的頂尖學者和專家發表合共六場精彩演說，分享政府部門在中藥質量控制方面的系統工作，以及業界和學界對名貴中藥的質量評價研究。

全國政協常務委員、香港特別行政區行政會議成員高永文醫生在論壇上介紹了「助推湘贛粵港澳中醫藥產業協同發展聯盟」的由來。聯盟由「中醫藥全產業鏈香港中心」統籌在港的建設，並將構建四個中醫藥發展合作中心，包括中藥材的種植、產業化、科研創新和商貿流通。

是次論壇旨在促進政界、產業界和學術界的交流與合作，進而推動中醫藥的標準化與國際化。 /

The School and HK Authentication Centre of Valuable Chinese Medicines jointly organised the 2023 HK Summit of Quality Control of Valuable Chinese Medicines on campus on 29 October 2023. The Summit attracted approximately 200 participants from the Government departments, Chinese medicine industry and academia.

The Summit featured six insightful lectures by distinguished scholars and experts from the Government departments, industry and academia, sharing the systematic work on the quality control of Chinese medicines by the Government, as well as the quality evaluation and scientific research on valuable Chinese medicines by the industry and academia.

At the Summit, Dr. Ko Wing-man, member of the Standing Committee of the National Committee of the Chinese People's Political Consultative Conference and of the Executive Council of the Hong Kong Special Administrative Region (HKSAR), explained the origins of the "Alliance for the Promotion of Collaborative Development of Traditional Chinese Medicine Industry in Hunan, Jiangxi, Guangdong, Hong Kong, and Macau". The Alliance's development and engagement in Hong Kong is coordinated by the "Hong Kong Centre for the Whole Industry Chain of Traditional Chinese Medicine". This strategic Alliance aims to establish four developmental collaboration centres, which will focus on crucial aspects of the industry, including the cultivation, industrialisation, research innovation, and commercial circulation of traditional Chinese medicinal materials.

The Summit was held to foster communications and collaborations among the Government departments, industry and academia, aiming to further advance the standardisation and internationalisation of traditional Chinese medicine. /

第二屆中醫遠程醫療國際研討會暨 國際遠程健康中醫研究協會年會順利舉行

The 2nd International Conference on Traditional Chinese Medicine Tele-healthcare cum Annual Meeting of TASTCMI concluded successfully



學院聯同世界針灸學會聯合會及國際遠程健康中醫研究協會在去年11月4日舉辦第二屆中醫遠程醫療國際研討會暨國際遠程健康中醫研究協會年會。會議以線上線下混合模式舉行，匯聚來自10個國家合共25位學者、中醫藥專家、業界精英，以及政府部門代表交流意見，共同探討中醫遠程醫療的發展。

是次活動吸引了約50名現場與會者及逾200名來自本地和海外的線上參加者，包括香港特別行政區行政會議成員高永文醫生、醫務衛生局中醫藥發展助理專員吳梓新博士，以及一眾中醫藥專家。/

SCM joined hands with the World Federation of Acupuncture and Moxibustion Societies and the Telehealth Association for the Study of Traditional Chinese Medicine International (TASTCMI) to host The 2nd International Conference on Traditional Chinese Medicine Tele-healthcare (ICTCMT) and Annual Meeting of TASTCMI on 4 November 2023. The conference, held in hybrid mode, brought together a total of 25 scholars, Chinese medicine experts, industry leaders from 10 countries, as well as Government representatives, to exchange views and explore TCM telemedicine development.

The event attracted around 50 on-site participants and over 200 online participants from Hong Kong and overseas, including Dr. Ko Wing-man, member of the Executive Council of HKSAR; Dr. Ng Chi-sun, Assistant Commissioner for Chinese Medicine Development of the Health Bureau; and a group of Chinese medicine experts. /

學院成立系統醫學與健康科學研究院

SCM establishes Institute of Systems Medicine and Health Sciences

系統醫學與健康科學研究院以中醫藥智慧和系統生物學理論為基礎，致力於解決健康問題。該院旨在將組學科學和人工智能方法與個體化疾病預測和預防相結合，促進藥物發現和診斷產品開發，培養跨學科人才，助力中醫藥現代化。 /

The Institute of Systems Medicine and Health Sciences (SMHS) is premised on holistic traditional Chinese medical views and systems biology approaches to address health issues. SHMS aims to integrate omics sciences and artificial intelligence methods with personalised disease prediction and prevention, facilitate drug discovery and diagnostic product development, nurture interdisciplinary talents, and contribute to TCM modernisation. /

中藥創新研發中心與北京盈科瑞創新醫藥攜手開發中藥

CDD and Beijing Increasepharm Corporation collaborate to develop Chinese medicine



中藥創新研發中心與北京盈科瑞創新醫藥於去年9月10日簽署戰略合作協議，共同開發中藥新藥和中藥大健康新產品。雙方將展開全方位合作，共建科研平台，致力於中藥新藥產品開發、已有傳統中藥的二次開發、已有產品或已有成果的技術轉讓、已有上市產品的行銷及產業化合作等，共同推進中醫藥傳承、創新和發展。 /

CDD has signed a strategic collaboration agreement with Beijing Increasepharm Corporation for the joint development of new drugs and health products based on Chinese medicine on 10 September 2023. Both parties will collaborate in establishing research and development platform for the development of new Chinese medicine drug products, secondary development of existing Chinese medicines, technology transfer of existing products or achievements, marketing and industrialisation of existing products, with a view to promoting the inheritance, innovation, and development of Chinese medicine. /

山東省委常委兼統戰部部長徐海榮常委率團 與學院代表交流分享

Delegation from Shandong Province exchanges views with SCM representatives



山東省委常委、統戰部部長徐海榮常委率領山東省濰坊市代表團，聯同政制及內地事務局局長曾國衛先生，於去年8月4日到訪浸大。代表團由浸大校長衛炳江教授、行政副校長暨秘書長鄒靄雲女士、協理副校長（中醫藥發展）兼學院臨床部主任卞兆祥教授接待。學院署理院長賈偉教授、副院長（教與學）李敏教授、教學科研部韓全斌教授亦參與是次交流會。/

A delegation led by Mr. Xu Hairong, Member of the Standing Committee and Head of the United Front Work Department of Shandong Provincial Party Committee, along with Mr. Erick Tsang,

Secretary for Constitutional and Mainland Affairs, visited HKBU on 4 August 2023. The delegation was received by Professor Alexander Wai, President and Vice-Chancellor; Ms. Christine Chow, Vice-President (Administration) and Secretary; and Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) and Director of CLNC at HKBU. Other attending SCM representatives included Professor Jia Wei, Acting Dean of Chinese Medicine; Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine; and Professor Simon Han, Professor of CMTR. /

獅子會與浸大中醫藥慈善基金任命新基金董事局主席及副主席 CMCF appoints new Foundation Chairman and Vice-Chairman



獅子會與香港浸會大學中醫藥慈善基金2024-25年度董事局周年會議暨第22次會議於去年12月5日舉行，一致選出浸大行政副校長暨秘書長鄒靄雲女士擔任基金董事局主席，林海涵博士，JP 為董事局副主席。新一屆董事及轄下委員會成員任期兩年，至2025年底。會上，成員討論了即將推行的籌募大使計劃，為表支持，董事文錦歡女士慷慨捐贈了港幣10萬元，顧問孔慶全先生則承諾按籌款總金額進行二比一的配對捐款。這些捐款將有助於基金實踐其使命，提供長者所需的中醫服務，並改善他們的生活質量。


慈善基金於去年12月2至3日參與香港電台在香港科學館露天廣場舉辦的《聲影穿梭 — 香港公共廣播九十五年》嘉年華活動。臨床部在現場設置《中醫與你》主題攤位，提供免費的中醫四診儀體質檢測服務、攤位遊戲和派發花茶，推廣中醫藥的疾病預防概念。攤位由慈善基金及屯門獅子會贊助。 /

At the Annual General Meeting cum the 22nd Meeting of the Board of Directors 2024-25 of Lions & HKBU Chinese Medicine Charity Foundation (CMCF), held on 5 December 2023, members agreed unanimously to appoint Ms. Christine Chow, Vice-President (Administration) and Secretary of HKBU, and Dr. Lam Hoi Ham, JP, as the Chairman and Vice-Chairman of the Foundation respectively. The term of appointment of the new Board Member and its Committee Members is for two years until the end of 2025. During the meeting, members discussed an upcoming fundraising ambassador plan. Ms. Mann Kam Foon, Teresa, generously donated HKD100,000 in support. Additionally, Mr. Hung Hing Chuen, Billy, pledged to make matching donations with a ratio of 2:1 based on the total amount raised. These generous contributions will help CMCF fulfill its mission to provide the necessary Chinese medicine services for the elderly and improving their quality of life.

On 2-3 December 2023, CMCF participated in the '95 Years of Public Service Broadcasting in Hong Kong "Sonic + Visual" Carnival' organised by Radio Television Hong Kong. CLNC set up a themed booth "Chinese Medicine and You", offering free body constitution assessments using the Chinese Medicine Four Diagnostic Instrument, games and herbal tea distribution, with a view to promoting the concept of disease prevention in Chinese medicine. The event was sponsored by CMCF and the Lions Club of Tuen Mun. /

2023-24 年度本科收生成績

2023-24 undergraduate admission



於 2023-24 學年，中醫學學士及生物醫學理學士（榮譽）學位課程和中藥學學士（榮譽）學位課程分別錄取了 47 名及 23 名學生。中醫課程更連續十二年成為大學收生成績平均分數最高的課程，兩個本科課程收生成績平穩。/

For the 2023-24 academic year, the Bachelor of Chinese Medicine and Bachelor of Science (Hons) in Biomedical Science (BCM) and Bachelor of Pharmacy (Hons) in Chinese Medicine (BPharm) programmes have admitted 47 and 23 students respectively. The BCM programme has ranked the top in the University in terms of average admission score for the twelfth consecutive year, while the admission results of both undergraduate programmes are steady. /

中醫本科生在中醫執業試取得佳績

BCM students achieve remarkable success in CMPLE

在疫情持續和網上教學的影響下，中醫本科生的學習及備試訓練仍有條不紊地進行。本年度中醫本科生的中醫執業資格試的合格率为 81.5%，成績維持在高水平。/

Under the influence of the pandemic and online teaching, BCM students' learning and preparation for the examination continued to be carried out in full swing. The pass rate of the BCM students sitting the Chinese Medicine Practitioners Licensing Examination (CMPLE) this year is 81.5%, maintaining a high level of achievement. /

學院舉辦聯招面試暨中醫藥學院大樓導賞日

SCM hosts JUPAS interview and guided tour

學院在去年 6 月 20 日舉辦聯招面試暨中醫藥學院大樓導賞日，獲邀出席面試的應屆香港中學文憑試考生參與課程資訊講座，從而了解學院背景，以及中醫和中藥課程的特色、學習活動、就業前景等。出席者更可報名參加中醫藥學院大樓的導賞活動，認識學院的教學及科研設施，學習中醫藥知識。/



The School hosted the JUPAS interview and guided tour of SCM building on 20 June 2023. HKDSE candidates this year who were invited to attend the interview joined the programme briefings to learn more about the background of SCM, and the curricular features, learning activities and career prospect for graduates of the BCM and BPharm programmes. Participants could also register for the guided tour of the School's teaching and research facilities to learn some basic knowledge about Chinese medicine. /



學院於浸大入學資訊日介紹本科課程

SCM introduces undergraduate programmes on HKBU Information Day

浸大於去年10月7日舉行入學資訊日，近300名中學生參加學院的入學資訊講座和問答環節。當天，中醫藥學院大樓開放給公眾參觀，超過800名學生參觀各項教學和研究設施，以及位於學院大樓的博物館。 /

HKBU Information Day was successfully held on 7 October 2023. Around 300 secondary school students attended the School's admission talks with Q&A sessions. With the SCM building opened to the public that day, more than 800 students visited the teaching and research facilities as well as the museum housed in the SCM building. /

持續及專業教育部舉辦副學位課程簡介會暨中醫藥文化推廣講座

DCPE hosts information session on sub-degree programmes and promotional talk on Chinese medicine culture

持續及專業教育部於去年5月20日舉行副學位課程簡介會暨中醫藥文化推廣講座，活動以線上線下混合模式進行，吸引逾90位來自社會各界的人士參加。講座以「飲食養生：原則及實例分享」為題，簡介中醫藥防病治病的理念和原則，向公眾推廣中醫藥文化和養生保健知識。 /

The Division of Continuing and Professional Education (DCPE) organised an information session on the sub-degree programmes offered by SCM and a promotional talk on Chinese medicine culture on 20 May 2023. The hybrid event attracted over 90 participants. The talk titled "Dietary Therapy: Principles and Case Studies" introduced the concepts and principles of TCM disease prevention and treatment, promoting TCM culture and healthcare knowledge to the public. /



副學位課程迎新會暨中醫藥文化學習分享會

Orientation and Chinese medicine culture sharing seminar for sub-degree programmes



持續及專業教育部於去年9月13日舉辦了一年一度的中醫藥副學位課程迎新會暨中醫藥文化學習分享會。教職員在活動上歡迎一眾新生，並祝賀他們開展中醫藥知識學習之旅。兩位學業成績優異的校友，包括中藥藥劑高等文憑課程畢業生梁慧賢女士和中醫學文憑課程畢業生兼資深傳媒人吳雨先生，BBS，應邀與同學分享他們的中醫藥文化學習體驗。 /

DCPE held the orientation and Chinese medicine culture sharing seminar for sub-degree programmes on 13 September 2023. Faculty members were in attendance to extend their warmest welcome to the new students, celebrating their new Chinese medicine learning journey. Two distinguished alumni, including Ms. Leung Wai Yin, graduate of the Advanced Diploma of Pharmacy in Chinese Medicine programme, and Mr. Ng Yu, BBS, a veteran media figure and graduate of the Diploma in Chinese Medicine programme, were invited to share their learning experience with the new students. /



於澳門和馬來西亞推廣本科課程

Promotion of undergraduate programmes in Macau and Malaysia

教學科研部副主任關曉儀博士於去年9月參加澳門國際學校升學展，向澳門國際學校的學生及教職員推廣學院開辦的中醫和中藥本科課程，參加人數超過800人，反應熱烈。 /

Dr. Anna Kwan, Associate Director of CMTR, attended the TIS University Fair in Macau last September. She promoted the BCM and BPharm undergraduate programmes offered by the School to the students and faculty members of International School of Macao. Around 800 participants attended the Fair. /



教學科研部客座副教授余堅文博士於去年11月參加馬來西亞吉隆坡中華獨立中學教育展，介紹學院的兩個本科課程，並接獲多個申請意向。 /

Dr. Kevin Yue, Adjunct Associate Professor of CMTR, attended the 2023 Chong Hwa Independent High School Education Fair in Malaysia last November, presenting the two undergraduate programmes offered by SCM. There was a remarkable surge in interest for SCM undergraduate programmes this year. /

學院聖誕聯歡晚會暨畢業生謝師宴

SCM Christmas Party and Graduation Dinner



學院於去年12月14日舉辦聖誕聯歡晚會，與逾400名參加者，包括榮休教授趙中振教授、學院諮詢委員會成員李應生先生，以及學院教職員、學生、校友、好友和合作夥伴聚首一堂，共慶佳節並維繫感情。一眾來賓全情投入參與遊戲和抽獎活動，享受精彩的歌唱表演，場面熱鬧。當晚，應屆本科畢業生向老師和為他們提供實習機會的機構代表表達由衷敬意。他們除了獻唱助慶，也播放精心製作的錄影片段，重溫他們的校園生活，藉此感謝多年來教導和幫助他們的老師和支持者。 /

SCM hosted the Christmas Party on 14 December 2023 to celebrate the festive season and foster relationships with over 400 participants, including Professor Zhao Zhongzhen, Professor Emeritus; Mr. Tommy Li, Member of SCM Advisory Committee; as well as staff, students, alumni, friends and partners of SCM. They were entertained throughout the evening with games, lucky draws and singing performances. At the event, the Class of 2023 expressed appreciation to their teachers and representatives from organisations which provided them with internship and practicum opportunities. They gave singing performances and presented a video which showed their campus life, conveying their gratitude to teachers and supporters who provided guidance and assistance to them during their undergraduate studies. /

本科生暑期交流團到訪內地大學

Undergraduate summer tours to universities in Mainland China



為擴闊學生視野，教學科研部舉辦了兩個暑期交流團，共18名中醫和中藥課程本科生分別到湖南中醫藥大學和南京中國藥科大學交流學習。學生通過參與課題講座、參觀各項設施及到訪附屬醫院，增進學術知識，體驗不同文化，並與當地大學的學生建立友誼。 /

To broaden students' horizons, CMTR organised two summer tours to Hunan University of Chinese Medicine and China Pharmaceutical University in Nanjing, with a total of 18 undergraduate students participating. Through attending lectures and visiting facilities housed in the universities and affiliated hospitals, students were able to deepen their academic knowledge, experience different cultures, and build friendships with students from local universities. /

新加坡南洋理工大學學生到訪學院

Students of Singapore Nanyang Technological University visit SCM

新加坡南洋理工大學（南大）中醫系的學生於去年8月16日到訪學院。通過是次訪問，南大學生認識到學院對香港中醫藥教學培訓上作出的貢獻，乃至學院、以及香港中醫藥專業的未來發展。 /

A group of Chinese medicine students from Nanyang Technological University, Singapore (NTU) visited SCM on 16 August 2023. Through this visit, NTU students recognised the contributions made by SCM to the teaching and training of traditional Chinese medicine in Hong Kong, as well as the future development of the School and the traditional Chinese medicine profession in Hong Kong. /



未來中醫中藥的蓬勃發展
形式：ZOOM 視像
語言：廣東話

中西醫協作的國際機遇
13 Nov 2023 (Mon) 5-6pm
講者：陳錦華博士
香港浸會大學中醫藥學院助理教授

香港中醫藥行業發展及就業趨勢
20 Nov 2023 (Mon) 5-6pm
講者：蔡文方先生
香港中醫藥管理委員會秘書長

香港中醫藥師的工作和前景
27 Nov 2023 (Mon) 5-6pm
講者：辜炳銳博士
香港浸會大學中醫藥學院主任講師

名額有限，截止報名日期為 11 月 6 日

網上講座系列推廣本科課程

Webinars for promotion of undergraduate programmes

教學科研部在去年11月舉行了「未來中醫中藥的蓬勃發展」網上講座系列，由助理教授陳錦華博士、中藥校友蔡文方先生及講師辜炳銳博士擔任講者，以中西醫協作的國際機遇、香港中藥行業發展及就業趨勢，以及香港中醫師的工作和前景為題，與一眾高中生分享學院畢業生的出路。 /

CMTR held a webinar series on the future development of Chinese medicine last November. Speakers included Dr. Chan Kam Wa, Assistant Professor of CMTR; Mr. Franky Choy, alumnus of BPharm programme; and Dr. Ku Ping Yui, Lecturer of CMTR. The webinars introduced international opportunities for collaboration between Chinese and Western medicine, development and employment trends of Chinese medicine industry, and work and prospects for Chinese medicine practitioners in Hong Kong, aiming to share the prospects of SCM alumni with secondary school students. /

學院博士生於第 19 屆 國際中醫藥研究生研討會獲獎

SCM doctoral students clinches awards at the
19th International Postgraduate Symposium on
Chinese Medicine

張宏杰教授的兩位博士研究生林柱城及陳柏森於第19屆國際中醫藥研究生研討會上榮獲「天江杯李時珍青年優秀論文獎」。林柱城進行天然產物對治療肥胖症及其相關代謝性疾病的研究，陳柏森則進行天然化合物抗結直腸癌的研究。Professor Zhang Hongjie's doctoral students Lam Chu Shing and Chen Baisen were honoured with the prestigious "Tianjiang Cup Li Shizhen Youth Outstanding Paper Award" in the 19th International Postgraduate Symposium on Chinese Medicine. Lam Chu Shing is engaged in research on natural products aimed at treating obesity and related metabolic diseases. Chen Baisen conducts research on natural compounds for the treatment of colorectal cancer. /

The 19th International Postgraduate Symposium on Chinese Medicine



Modern Products
國際現代化中醫藥及健康產品會議

The 19th International Postgraduate Symposium on Chinese Medicine



學院博士生獲頒 郭鍾寶芬博士生 卓越研究獎

SCM doctoral student wins
Madam Kwok Chung Bo Fun
PhD Student Research
Excellence Award

博士研究生蘇成福獲頒2023/24
年度郭鍾寶芬博士生卓越研究獎
第一名。在副院長(教與學)李

敏教授的指導下，蘇成福在中藥藥理研究領域做出了重要貢獻。他參與了兩個研究項目，發現了中藥化合物雷公藤紅素，以及揭示了 (-) 五味子乙素的新機制，分別具備治療阿茲海默症和帕金森症的潛力。PhD student Su Chengfu has been awarded the first prize of the Madam Kwok Chung Bo Fun PhD Student Research Excellence Award 2023/24. Under the supervision of Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine, Su Chengfu has made significant contributions to the field of Chinese medicine pharmacological study. He has been engaged in two research projects, identifying a Chinese medicine compound Celastrol and revealing a novel mechanism of (-)Schisandrin B, which have shown potential for the treatment of Alzheimer's Disease and Parkinson's disease respectively. /

兩名傑出中醫學生獲頒 香港賽馬會本科獎學金

Two outstanding BCM students
clinch The Hong Kong Jockey Club
Undergraduate Scholarships

兩名中醫學學士及生物醫學理學士學生劉芷伊和蘇俊一獲頒2022-23年度香港賽馬會本科獎學金，以表揚他們在學業上的卓越表現和熱心參與社會事務。香港賽馬會慈善信託基金在去年11月2日的晚宴上，並頒發獎學金予4名浸大本科生，當中兩名來自中醫藥學院。是項獎學金不僅是對他們的努力和熱心服務社會的肯定，也證明了他們具潛力成為中醫界別的未來領袖。Two outstanding students from the BCM programme, Lau Zhi-yi and So Chun-yat, have been awarded 2022-23 The Hong Kong Jockey Club Undergraduate Scholarships in recognition of their outstanding academic performance and commitment to serving the community. The Hong Kong Jockey Club Charities Trust granted new scholarships to 4 HKBU undergraduate students on 2 November 2023, 2 of whom are from SCM. This prestigious scholarship not only recognises their hard work and commitment but also serves as a testament to their potential as future leaders in the field of Chinese medicine. /



中醫藥學會迎新營

Orientation camp by the HKBU Chinese
Medicine Society

香港浸會大學中醫藥學會於去年8月21至23日在香港浸會園舉辦了一年一度的迎新營，是次活動復辦了實體營火舞會，水戰以及團體遊戲。各新生在開學前與同學、師兄師姊們一同玩樂，建立良好關係。The HKBU Chinese Medicine Society held its annual orientation camp on 21-23 August 2023 at the Hong Kong Baptist Park. The event brought back a live campfire dance, water battles, and team games. The new students had the opportunity to enjoy themselves with their peers and senior students before the school term began, fostering good relationships. /

中藥學會

2023-24 年度迎新營

2023-24 orientation camp of The Society of Chinese Materia Medica

香港浸會大學中藥學會於去年8月28至30日舉辦了迎新營，讓新生能在開學前認識新朋友和適應大學生活。The Society of Chinese Materia Medica organised an orientation camp from 28 to 30 August 2023, allowing new students to make new friends and adapt to university life before the start of the semester. /



修課式中醫藥碩士學位課程喜迎 342 名新同學

Welcoming 342 new students from taught postgraduate programmes

為迎接 342 位入讀修課式中醫藥碩士學位課程的新生，持續及專業教育部策劃了一年一度的迎新活動。老師們歡迎和勉勵同學們珍惜學習機會，盡快適應碩士生涯，收穫知識和學習體驗。DCPE organised an annual orientation to welcome 342 freshmen of the taught postgraduate programmes offered by SCM. Faculty members encouraged students to appreciate the learning opportunities and engaged in their studies quickly. They also anticipated that students would gain valuable knowledge and experience during their studies. /



中醫健康管理 理學碩士學位課程 重啟交流活動

Exchange tour of Master of Science in Personal Health Management (Chinese Medicine) programme resumes


去年5月，中醫健康管理理學碩士學位課程的內地實踐研習活動重新啟動，同學們獲安排前往福建中醫藥大學及其附屬醫院和健康管理中心交流學習。學生除了親身參與臨床診療外，又與該校碩士和博士研究生進行學術交流。The Master of Science in Personal Health Management (Chinese Medicine) programme resumed Mainland practicum and academic exchange activities last May. Students visited Fujian University of Traditional Chinese Medicine, its affiliated hospital and Health Management Center. They participated in clinical diagnosis and treatment, engaged in academic exchanges with master's and doctoral students. /

《中振話綱目——走出書齋探本草》

主編：趙中振

《中振話綱目——走出書齋探本草》（一套四冊）以編者在國內超過三十個藥材主產區的考察和海外七大洲的實地調查為基礎，從博物學和世界傳統藥物學的角度對《本草綱目》進行了深度和系統的解讀。

本書參照《本草綱目》的結構，逐一解析中藥。內容涉及植物、動物、礦物，介紹了它們在大自然中的形態、生存環境等科學知識，以及所承載的醫藥飲食、民俗掌故、中外交流等方面的歷史文化知識。該書適合中醫文化愛好者閱讀，也是向中學生普及中醫藥知識的重要參考。



《2019冠狀病毒病醫案選粹》

主編：呂愛平、卞兆祥、彭波

2022年初香港爆發第五波新冠疫情，浸大迅速組織了中醫抗疫醫療隊，全力參與防治工作，全面支援社區，更獲政府社會福利署委任為啟德暫託中心的營運機構之一，派出中醫師隊伍為入住的輕症長者提供以中醫為主的治療服務。浸大中醫師隊伍從中積累了豐富的治療經驗，本書集結和分享相關醫案，讓後學可以從中汲取精華，貫通所學的知識，探尋臨床診治的規律；而同道也可以加以發揮，運用於自己的臨床實踐，提高治病的療效。

聯絡我們
Contact Us

香港浸會大學中醫藥學院

九龍塘浸會大學道七號賽馬會中醫藥學院大樓

School of Chinese Medicine, Hong Kong Baptist University

Jockey Club School of Chinese Medicine Building,
7 Baptist University Road, Kowloon Tong, Kowloon.

院長辦公室 Dean's Office

四樓 4/F

電話 Tel (852) 3411 2457
傳真 Fax (852) 3411 2917
電郵 Email scmd@hkbu.edu.hk

教學科研部 Teaching and Research Division

四樓 4/F

電話 Tel (852) 3411 2481
傳真 Fax (852) 3411 2461
電郵 Email cmtr@hkbu.edu.hk

技術開發部 Technology Development Division

四樓 4/F

電話 Tel (852) 3411 2945
傳真 Fax (852) 3411 2902
電郵 Email scmtdd@hkbu.edu.hk

臨床部 Clinical Division

三樓 3/F

電話 Tel (852) 3411 2968 / (852) 3411 2988
傳真 Fax (852) 3411 2929
電郵 Email scmcl@hkbu.edu.hk

持續及專業教育部 Division of Continuing & Professional Education

四樓417室 Rm417, 4/F

電話 Tel (852) 3411 2912 / (852) 3411 5748
傳真 Fax (852) 3411 2918
電郵 Email dcpe@hkbu.edu.hk

秘書處 Secretariat

四樓 4/F

電話 Tel (852) 3411 5387
傳真 Fax (852) 3411 2902
電郵 Email scm@hkbu.edu.hk

學院網頁 | SCM Website
<http://scm.hkbu.edu.hk>



學院 LinkedIn |
SCM LinkedIn
School of Chinese
Medicine, HKBU



學院 IG | SCM IG
hkbuscm



學院 FB | SCM FB
scm.hkbu

